title: Replicating poxviruses for human cancer therapy.
abstract: Naturally occurring oncolytic viruses are live, replication-proficient viruses that specifically infect human cancer cells while sparing normal cell counterparts. Since the eradication of smallpox in the 1970s with the aid of vaccinia viruses, the vaccinia viruses and other genera of poxviruses have shown various degrees of safety and efficacy in pre-clinical or clinical application for human anti-cancer therapeutics. Furthermore, we have recently discovered that cellular tumor suppressor genes are important in determining poxviral oncolytic tropism. Since carcinogenesis is a multi-step process involving accumulation of both oncogene and tumor suppressor gene abnormalities, it is interesting that poxvirus can exploit abnormal cellular tumor suppressor signaling for its oncolytic specificity and efficacy. Many tumor suppressor genes such as p53, ATM, and RB are known to play important roles in genomic fidelity/maintenance. Thus, tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to accumulation of genetic defects, which would in turn result in oncolytic virus susceptibility. This review outlines the characteristics of oncolytic poxvirus strains, including vaccinia, myxoma, and squirrelpox virus, recent progress in elucidating the molecular connection between oncogene/tumor suppressor gene abnormalities and poxviral oncolytic tropism, and the associated preclinical/clinical implications. I would also like to propose future directions in the utility of poxviruses for oncolytic virotherapy.
authors.affiliation: Department of Medical Science, Dankook University College of Medicine, Cheonan, 330-714, Republic of Korea, manbok66@dankook.ac.kr.
authors.forename: Manbok
authors.initials: M
authors.lastname: Kim
mesh_terms: D045744:Cell Line, Tumor; D016147:Genes, Tumor Suppressor; D006801:Humans; D009233:Myxoma virus / Q000502:physiology; D009369:Neoplasms / Q000628:therapy*; D009857:Oncogenes; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000502:physiology*; D011212:Poxviridae / Q000502:physiology*; D014616:Vaccinia virus / Q000502:physiology; D056189:Viral Tropism; D014779:Virus Replication
references.citation: Viruses. 2014 May 16;6(5):2122-37
references.pmid: 24841386
references.citation: J Immunother. 2001 Jan-Feb;24(1):46-57
references.pmid: 11211148
references.citation: Arch Virol. 1975;49(2-3):217-27
references.pmid: 813616
references.citation: Vaccine. 2006 Nov 17;24(47-48):7009-22
references.pmid: 17052815
references.citation: Vet Rec. 1996 May 25;138(21):527
references.pmid: 8761982
references.citation: Annu Rev Virol. 2014 Sep 1;1(1):119-141
references.pmid: 25839047
references.citation: Cell Mol Life Sci. 2012 Jun;69(12):2009-24
references.pmid: 22223110
references.citation: Lab Anim Sci. 1971 Dec;21(6):1023-31
references.pmid: 4331925
references.citation: Cancer Res. 2001 Dec 15;61(24):8751-7
references.pmid: 11751395
references.citation: Am J Epidemiol. 1971 Nov;94(5):514-9
references.pmid: 5166040
references.citation: Nat Biotechnol. 2012 Jul 10;30(7):658-70
references.pmid: 22781695
references.citation: Vet Comp Oncol. 2016 Dec;14(4):395-408
references.pmid: 25302859
references.citation: Trends Microbiol. 2001 Sep;9(9):459-60
references.pmid: 11553459
references.citation: Mol Ther. 2010 May;18(5):896-902
references.pmid: 20160706
references.citation: Future Oncol. 2012 Mar;8(3):231-7
references.pmid: 22409460
references.citation: Proc Biol Sci. 2002 Mar 7;269(1490):529-33
references.pmid: 11886647
references.citation: Nature. 1958 Jul 19;182(4629):195-6
references.pmid: 13566242
references.citation: Rev Sci Tech. 2010 Apr;29(1):103-11
references.pmid: 20617651
references.citation: PLoS One. 2014 Feb 21;9(2):e89521
references.pmid: 24586845
references.citation: J Gen Virol. 2006 Aug;87(Pt 8):2115-2125
references.pmid: 16847106
references.citation: J Infect Dis. 1977 Sep;136(3):453-5
references.pmid: 198484
references.citation: Nat Med. 2013 Mar;19(3):329-36
references.pmid: 23396206
references.citation: Oncogene. 2007 Jun 14;26(28):4124-34
references.pmid: 17213803
references.citation: Gene Ther. 2010 Feb;17(2):281-7
references.pmid: 19890355
references.citation: Arch Virol. 1989;106(1-2):127-39
references.pmid: 2669685
references.citation: Gynecol Oncol. 2014 Mar;132(3):722-9
references.pmid: 24434058
references.citation: EMBO J. 1998 Jun 15;17(12):3351-62
references.pmid: 9628872
references.citation: J Virol. 2004 Nov;78(22):12471-9
references.pmid: 15507634
references.citation: Mol Ther. 2015 Jan;23(1):202-14
references.pmid: 25292189
references.citation: Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51
references.pmid: 1438287
references.citation: Mol Gen Mikrobiol Virusol. 2012;(1):8-15
references.pmid: 22702138
references.citation: Oncogene. 2010 Jul 8;29(27):3990-6
references.pmid: 20473328
references.citation: Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):423-30
references.pmid: 12818626
references.citation: Cancer J. 2011 Sep-Oct;17(5):359-71
references.pmid: 21952287
references.citation: Nature. 1985 Oct 31-Nov 6;317(6040):813-5
references.pmid: 4058585
references.citation: J Virol. 2005 Sep;79(18):11873-91
references.pmid: 16140764
references.citation: Gene Ther. 2000 Jul;7(14):1217-23
references.pmid: 10918490
references.citation: Gynecol Oncol. 2011 Feb;120(2):302-10
references.pmid: 21145097
references.citation: Cancer Res. 2005 Nov 1;65(21):9982-9990
references.pmid: 16267023
references.citation: Oncol Res. 1999;11(3):133-44
references.pmid: 10527073
references.citation: Proc R Soc Lond B Biol Sci. 1983 Jun 22;218(1212):259-85
references.pmid: 6136042
references.citation: Dtsch Med Wochenschr. 1974 Nov 22;99(47):2386-92
references.pmid: 4426258
references.citation: J Virol. 2003 May;77(10):5877-88
references.pmid: 12719581
references.citation: Semin Pediatr Infect Dis. 2003 Jul;14(3):189-95
references.pmid: 12913830
references.citation: J Virol. 2001 Jan;75(2):850-6
references.pmid: 11134298
references.citation: Arch Virol. 1998;143(12):2289-303
references.pmid: 9930187
references.citation: Int J Cancer. 2015 Mar 1;136(5):1065-72
references.pmid: 25042001
references.citation: Cancer Res. 1999 Jul 15;59(14):3396-403
references.pmid: 10416601
references.citation: Mol Ther. 2011 Jun;19(6):1107-15
references.pmid: 21386827
references.citation: Nat Rev Microbiol. 2005 Mar;3(3):201-13
references.pmid: 15738948
references.citation: Nat Rev Cancer. 2005 Dec;5(12):965-76
references.pmid: 16294217
references.citation: Emerg Infect Dis. 2001 Nov-Dec;7(6):920-6
references.pmid: 11747717
references.citation: JAMA. 2003 Jun 25;289(24):3283-9
references.pmid: 12824210
references.citation: Lancet Oncol. 2008 Jun;9(6):533-42
references.pmid: 18495536
references.citation: Cancer Res. 2014 Dec 15;74(24):7260-73
references.pmid: 25336188
references.citation: Br Med J. 1971 Feb 13;1(5745):363-8
references.pmid: 5541925
references.citation: Mol Ther. 2010 May;18(5):888-95
references.pmid: 20234341
references.citation: Virology. 1989 Sep;172(1):116-24
references.pmid: 2773312
references.citation: J Neurooncol. 2011 Sep;104(3):715-27
references.pmid: 21607667
references.citation: Vaccine. 1997 Mar;15(4):387-94
references.pmid: 9141209
references.citation: Drug Des Devel Ther. 2010 May 25;4:71-9
references.pmid: 20531961
references.citation: Cancer Res. 1999 Oct 1;59(19):4955-63
references.pmid: 10519409
references.citation: Antiviral Res. 2009 Oct;84(1):1-13
references.pmid: 19563829
references.citation: J Urol. 2001 Oct;166(4):1291-5
references.pmid: 11547060
references.citation: J Biol Chem. 2004 Dec 10;279(50):52210-7
references.pmid: 15471883
references.citation: Gene Ther. 2007 Jan;14(1):20-9
references.pmid: 16915291
references.citation: J Clin Invest. 2007 Nov;117(11):3350-8
references.pmid: 17965776
references.citation: Cancer Gene Ther. 1999 Sep-Oct;6(5):409-22
references.pmid: 10505851
references.citation: Breast Cancer Res Treat. 2014 Dec;148(3):489-99
references.pmid: 25391896
references.citation: Virology. 1998 May 10;244(2):365-96
references.pmid: 9601507
references.citation: Proc Soc Exp Biol Med. 1953 Feb;82(2):298-301
references.pmid: 13037878
references.citation: J Virol. 1992 Aug;66(8):4720-31
references.pmid: 1629952
references.citation: Cancer Res. 2007 Oct 15;67(20):10038-46
references.pmid: 17942938
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4640-5
references.pmid: 16537421
references.citation: Curr Opin Mol Ther. 2006 Aug;8(4):314-21
references.pmid: 16955694
references.citation: Epidemiol Infect. 2009 Feb;137(2):257-65
references.pmid: 18606024
references.citation: Expert Rev Vaccines. 2013 Dec;12(12):1395-416
references.pmid: 24168097
references.citation: Infection. 1998 Sep-Oct;26(5):263-9
references.pmid: 9795781
references.citation: Leukemia. 2009 Dec;23(12):2313-7
references.pmid: 19865109
references.citation: J Virol. 1998 Mar;72(3):2429-38
references.pmid: 9499104
references.citation: Zentralbl Bakteriol B. 1978 Dec;167(5-6):375-90
references.pmid: 219640
references.citation: Cancer Gene Ther. 2000 Jan;7(1):66-73
references.pmid: 10678358
references.citation: J Virol. 2001 Nov;75(21):10300-8
references.pmid: 11581398
references.citation: Zentralbl Bakteriol Orig A. 1975;230(3):283-97
references.pmid: 1146441
references.citation: PLoS Pathog. 2012;8(10):e1002950
references.pmid: 23055928
references.citation: Virology. 2005 Mar 15;333(2):263-70
references.pmid: 15721360